🔗 Share this article

Given that the United States continues making sweeping changes to its vaccine guidelines, a particular individual appears somewhat surprisingly: Høeg, a Danish American sports physician and public health researcher who rose to prominence by expressing skepticism about COVID-19 vaccines throughout the pandemic and has focused upon alleged fatalities after COVID-19 vaccination in her short position at the FDA.

Proposed Shifts to Pediatric Immunization Schedule

Public health authorities were set to unveil radical changes to the pediatric immunization program recently, bringing the US with the Danish immunization schedule, according to reports – a substantial departure that would put the US at odds with much of the international standard with insufficient data for benefit. This reveal has been postponed until the new year.

In place of Vinay Prasad, Tracy Beth Høeg is scheduled to speak at the meeting. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the division this year.

Consolidating Power at the FDA

The acting appointment could signify a closer partnership between the drug and vaccine divisions as Dr. Høeg and Dr. Prasad strengthen their influence at the agency – and it suggests a renewed priority upon reevaluating already-approved immunizations at the FDA.

The new acting director has frequently advocated for ending some pediatric immunization guidelines in the US so as to align more similar to the Danish model, a country with comprehensive healthcare and a number of inhabitants about the population of the state of Wisconsin.

In her initial statements, she has kept her attention on vaccination policy – usually the responsibility of Dr. Prasad, chief of the FDA’s CBER – as opposed to drug regulation.

Questions Over Qualifications

Dr. Høeg has no apparent background in medication creation, regulation or administrative roles, which has been typical for previous directors of the biologics center. She has served at the FDA as a key advisor to the agency head and CBER since March.

“It seems she lacks to have the requisite experience” for running the pharmaceutical oversight division, stated Jonathan Howard. “She lacks experience running a scientific study. She lacks experience in running a large organization. She is not an expert in drug approvals.”

Former directors of the center would “understand regulatory frameworks and the research of drug development”, said Janet Woodcock. “Frankly, she has not acquired the kind of background that prior appointees who led the center have had.”

The drug center has an vast portfolio at the agency, Woodcock emphasized.

“Many people just zeroes in on the new drug program, but the generic drug division approves thousands of off-brand pharmaceuticals. There’s a biosimilars program, over-the-counter program and other areas, and every single one need to be supervised,” Woodcock explained. “The area you don’t keep your eye on, that is precisely what that I always told people is going to bite you.”

Additionally, a major administrative element to the role, which oversees in excess of 5,000 employees. “It’s a massive administrative position, if you execute it properly,” Woodcock concluded.

Official Statement and Contentious Policies

Regarding questions about Dr. Høeg's fitness for the role and whether this assignment indicates increased cooperation among agency officials on vaccines, a spokesperson responded that the “inquiries stem from flawed presumptions”.

“Her experience is consistent with the functions of her position,” the official explained, noting the months Høeg spent guiding the FDA commissioner on “pharmaceutical safety and approval science, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Høeg takes over the agency head's new expedited review system, a controversial rapid medication authorization process that allegedly troubled her former heads. “By what process are these drugs being picked for this expedited pathway? Who makes the decisions?” Howard said. “There’s a lot of lack of transparency happening at the FDA right now.”

In general, he remarked, “the agency looks to be trending towards laxer rules of pharmaceuticals, aside from immunizations.”

Established Track Record on Immunizations

With vaccines, Høeg has a more documented, if troubling, history, some experts said. She authored a analysis using unverified crowd-sourced reports to determine the frequency of myocarditis following Covid immunization. She counseled the state of Florida top health official Joseph Ladapo, who allegedly have modified findings to imply COVID-19 vaccines are more dangerous than they are.

Among her “policy goals” for the current federal leadership included changing regulations for new vaccines and discontinuing “optional” immunizations, she said after the election on a podcast. At the FDA, Høeg has according to sources suggested excluding young men from obtaining Covid vaccinations.

“She’s an thorough true believer who commences with her preconceived notions and works backwards to retrofit the evidence in a highly disingenuous, dishonest way,” Dr. Howard stated.

Consolidating Power and a “Push for Payback”

Høeg aligned with fellow contrarians, {like|